Twitter

Chordate granted new patent by the European Patent Office

Chordate Medical Holding AB (publ), (“Chordate,” “the Company”) announces that the European Patent Office has granted Chordate’s patent application EP 20163024.1 from 2020. The patent application pertains to the company’s treatment technique Ozilia, especially targeting chronic migraine.

“The purpose of further expanding the patent portfolio is to make it more difficult for a potential competitor to enter our market. The company’s intellectual property enables exclusivity in the market, which is a cornerstone of the value that the company is building,” says Anders Weilandt, CEO of Chordate Medical.

Chordate Medical now holds 78 patents distributed across 9 patent families, providing protection for various aspects of the company’s treatment techniques in 32 countries/regions. The granting and validation of application EP 20163024.1 mean that additional patents have been added to a growing portfolio that the company began building in 2008.

More posts

Press releases

If you want to read our press releases, there are available in the Investor Relations section or by clicking the link below.

Press releases

For questions about Chordate’s share price or other investment-related topics, please see if the answer is here.

For questions about the medical effects of Ozilia® Migraine, please see if the answer is here.

To get in touch with Chordate regarding other questions, use the adjecent form. We do our best to respond as quickly as possible.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.

Contact us

  • This field is for validation purposes and should be left unchanged.

The information is handled according to our privacy policy

Chordate Medical Holding AB (publ) is a medical technology company that has developed, patented and CE-marked Ozilia® Migraine (formerly K.O.S), a neuromodulation and drug-free treatment technology for chronic migraine and chronic rhinitis. The treatment has clinically proven efficacy according to a recent study, and is marketed in selected markets in the EU and the Middle East. Chordate Medical is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH). 

The company’s Certified Adviser on Nasdaq First North Growth Market Stockholm is Vator Securities AB.

Press releases

Chordate Medical AB

c/o Regus, Kistagången 20B
SE-164 40 Kista
Sweden

Privacy policy

Twitter